MarketPeel
Insider Trading Intelligence
Pricing
…
FL

Frank X. Leonard

NVCR
CHIEF DEVELOPMENT OFFICER · NOVOCURE LTD · CIK 0001822879
FILING MIX · LIFETIME29%/71%
BUYS
31
SELLS
76
TOTAL VALUE
$27.68M
COMPANIES
1
ACTIVE SINCE
Sep 2020
HOLDINGS NOW
461,425
AVG SELL PX
$54.92
TRADE KIND
SHOWING 107 / 107
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
63 backtested trades · 8 horizons · 17 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Frank X. Leonard, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d63+58.73%-2.54%+0.25%-2.79%-2.07%-1.96
14d63+55.56%-5.07%-0.49%-4.57%-6.76%-2.34
30d63+82.54%-6.94%-0.28%-6.65%-6.08%-2.91
60d63+84.13%-10.13%+1.51%-11.64%-10.16%-4.15
90d63+66.67%-4.61%+4.21%-10.50%-5.68%-3.02
180d63(3 pending)+85.00%-27.99%+7.85%-35.84%-32.45%-7.46
1y63(3 pending)+85.00%-58.47%+17.29%-78.83%-87.37%-16.03
2y63(11 pending)+100.00%-71.72%+44.45%-116.17%-121.99%-34.17
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
NVCR · 461,425 shares · as of Jun 30, 2026
0124,850249,700374,550499,400202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 31 buys / 76 sellsCOVERAGE · 24 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
1,905$11.15$21.2K461,425Jun 30, 2026Jul 1, 2026 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Executive Officer
34,273$17.93$614.6K459,520Jun 4, 2026Jun 5, 2026 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Executive Officer
5,607$13.31$74.6K493,793Mar 4, 2026Mar 5, 2026 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
150,000——499,400Mar 3, 2026Mar 5, 2026 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
216,388——216,388Mar 3, 2026Mar 5, 2026 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Executive Officer
7,232$13.49$97.6K349,400Mar 2, 2026Mar 3, 2026 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
18,621——356,632Feb 28, 2026Mar 3, 2026 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Executive Officer
9,734$13.66$133.0K338,011Feb 27, 2026Mar 3, 2026 ↗View →
NVCR
NOVOCURE LTD
SALE
EVP, Pres., Novocure Oncology
966$12.81$12.4K347,745Nov 1, 2025Nov 4, 2025 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
833$15.13$12.6K348,711Jun 30, 2025Jul 1, 2025 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
179,426——347,878Jun 4, 2025Jun 6, 2025 ↗View →
NVCR
NOVOCURE LTD
SALE10b5-1
10b5-1 plan
6,600$17.99$118.7K170,331Jun 2, 2025Jun 4, 2025 ↗View →
NVCR
NOVOCURE LTD
SALE10b5-1
10b5-1 plan
21,717$17.22$374.0K176,931Jun 2, 2025Jun 4, 2025 ↗View →
NVCR
NOVOCURE LTD
SALE10b5-1
10b5-1 plan
1,879$19.01$35.7K168,452Jun 2, 2025Jun 4, 2025 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
81,499$18.19$1.48M81,499Mar 4, 2025Mar 6, 2025 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
54,975$18.19$1000.0K198,648Mar 4, 2025Mar 6, 2025 ↗View →
NVCR
NOVOCURE LTD
SALE
EVP, Pres., Novocure Oncology
2,527$18.54$46.8K143,673Mar 3, 2025Mar 4, 2025 ↗View →
NVCR
NOVOCURE LTD
SALE
EVP, Pres., Novocure Oncology
2,770$18.28$50.6K146,200Feb 28, 2025Mar 3, 2025 ↗View →
NVCR
NOVOCURE LTD
SALE
EVP, Pres., Novocure Oncology
2,770$18.28$50.6K146,200Feb 28, 2025Mar 3, 2025 ↗View →
NVCR
NOVOCURE LTD
SALE
EVP, Pres., Novocure Oncology
10,277$19.92$204.7K150,959Feb 27, 2025Mar 3, 2025 ↗View →
NVCR
NOVOCURE LTD
SALE
EVP, Pres., Novocure Oncology
1,989$20.55$40.9K148,970Feb 27, 2025Mar 3, 2025 ↗View →
NVCR
NOVOCURE LTD
SALE
EVP, Pres., Novocure Oncology
10,277$19.92$204.7K150,959Feb 27, 2025Mar 3, 2025 ↗View →
NVCR
NOVOCURE LTD
SALE
EVP, Pres., Novocure Oncology
1,989$20.55$40.9K148,970Feb 27, 2025Mar 3, 2025 ↗View →
NVCR
NOVOCURE LTD
SALE
EVP, Pres., Novocure Oncology
598$15.94$9.5K161,236Nov 1, 2024Nov 4, 2024 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
1,736$12.24$21.2K161,834Jun 28, 2024Aug 6, 2024 ↗View →
NVCR
NOVOCURE LTD
SALE
EVP, Pres., Novocure Oncology
840$16.01$13.4K160,098Mar 4, 2024Mar 5, 2024 ↗View →
NVCR
NOVOCURE LTD
SALE
EVP, Pres., Novocure Oncology
1,679$16.03$26.9K160,938Mar 1, 2024Mar 5, 2024 ↗View →
NVCR
NOVOCURE LTD
SALE
EVP, Pres., Novocure Oncology
2,078$16.14$33.5K162,617Feb 28, 2024Feb 29, 2024 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
102,249$16.30$1.67M164,695Feb 27, 2024Feb 29, 2024 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
156,348$16.30$2.55M156,348Feb 27, 2024Feb 29, 2024 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
6,003$75.00$450.2K56,599Mar 7, 2023Mar 7, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
2,315$75.59$175.0K54,284Mar 7, 2023Mar 7, 2023 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
11,808——69,952Mar 3, 2023Mar 6, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
2,059$77.64$159.9K67,893Mar 3, 2023Mar 6, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
4,403$76.16$335.3K63,490Mar 3, 2023Mar 7, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
888$76.16$67.6K62,602Mar 3, 2023Mar 7, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
3,799$75.32$286.2K59,296Mar 2, 2023Mar 3, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
308$76.05$23.4K58,988Mar 2, 2023Mar 3, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
844$75.28$63.5K58,144Mar 2, 2023Mar 6, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
1,684$76.36$128.6K63,095Mar 1, 2023Mar 2, 2023 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
30,971$76.97$2.38M30,971Feb 28, 2023Mar 2, 2023 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
18,621——64,779Feb 28, 2023Mar 2, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
5,517——0Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
7,826——0Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
PURCHASE
President, CNS Cancers US
7,826$14.37$112.5K53,984Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
2,345$119.01$279.1K48,111Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
7,500——0Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
7,826$108.00$845.2K46,158Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
PURCHASE
President, CNS Cancers US
7,183$21.15$151.9K53,341Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
526$115.03$60.5K47,168Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
PURCHASE
President, CNS Cancers US
5,517$7.15$39.4K51,675Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
7,183$114.00$818.9K46,158Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
1,010$117.00$118.2K46,158Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
7,183——17,662Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
7,500$108.00$810.0K46,158Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
7,183——10,479Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
7,183$120.00$862.0K46,158Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
PURCHASE
President, CNS Cancers US
7,500$11.46$86.0K53,658Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
417$108.00$45.0K47,694Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
5,517$108.00$595.8K46,158Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
11,609$73.20$849.8K11,609Nov 1, 2022Nov 3, 2022 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
6,830——50,456Nov 1, 2022Nov 3, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
6,754$76.01$513.4K43,626Oct 13, 2022Oct 17, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
6,754$84.37$569.8K50,380Oct 6, 2022Oct 7, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
6,754$77.35$522.4K57,134Sep 29, 2022Sep 30, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
President, CNS Cancers US
6,754$77.00$520.1K63,888Sep 22, 2022Sep 26, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
6,754$87.31$589.7K76,159Sep 15, 2022Sep 19, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
5,517$90.00$496.5K70,642Sep 15, 2022Sep 19, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
5,517——5,517Sep 15, 2022Sep 19, 2022 ↗View →
NVCR
NOVOCURE LTD
PURCHASE
Chief Development Officer
5,517$7.15$39.4K82,913Sep 15, 2022Sep 19, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
1,863$88.00$163.9K84,150Sep 9, 2022Sep 12, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
6,754$81.48$550.3K77,396Sep 8, 2022Sep 13, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
1,384$78.57$108.7K86,013Sep 6, 2022Sep 7, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
584$79.04$46.2K87,397Sep 2, 2022Sep 6, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
360$77.06$27.7K88,467Sep 1, 2022Sep 6, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
240$75.88$18.2K88,827Sep 1, 2022Sep 6, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
438$78.14$34.2K88,029Sep 1, 2022Sep 6, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
452$78.66$35.6K95,825Sep 1, 2022Sep 6, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
2,720$77.92$211.9K90,155Sep 1, 2022Sep 6, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
1,088$78.68$85.6K89,067Sep 1, 2022Sep 6, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
1,047$75.94$79.5K101,146Sep 1, 2022Sep 6, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
1,750$76.96$134.7K92,875Sep 1, 2022Sep 6, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
48$78.96$3.8K87,981Sep 1, 2022Sep 6, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
2,955$78.09$230.7K96,277Sep 1, 2022Sep 6, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
1,200$75.93$91.1K94,625Sep 1, 2022Sep 6, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
1,914$77.00$147.4K99,232Sep 1, 2022Sep 6, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
414$69.66$28.8K102,193Aug 2, 2022Aug 3, 2022 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
312$59.08$18.4K102,607Jul 5, 2022Jul 7, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
744$70.10$52.2K102,295Mar 8, 2022Mar 9, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
555$70.41$39.1K103,039Mar 4, 2022Mar 7, 2022 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
4,933$80.59$397.6K4,933Mar 3, 2022Mar 7, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
930$74.50$69.3K103,594Mar 3, 2022Mar 7, 2022 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
30,422$80.59$2.45M30,422Mar 3, 2022Mar 7, 2022 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
17,371——104,524Mar 3, 2022Mar 7, 2022 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
540$138.23$74.6K87,153Sep 2, 2021Sep 7, 2021 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
328$149.43$49.0K89,158Aug 3, 2021Aug 4, 2021 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
713$149.38$106.5K89,486Aug 2, 2021Aug 4, 2021 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
154$137.12$21.1K90,199Jul 6, 2021Jul 8, 2021 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
765$130.81$100.1K90,045Mar 8, 2021Mar 10, 2021 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
567$137.55$78.0K90,810Mar 4, 2021Mar 8, 2021 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
16,003——16,003Mar 2, 2021Mar 4, 2021 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
8,709——91,377Mar 2, 2021Mar 4, 2021 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
430$152.05$65.4K82,668Mar 2, 2021Mar 4, 2021 ↗View →
NVCR
NOVOCURE LTD
PURCHASE
Chief Development Officer
1,465$149.10$218.4K83,098Feb 27, 2021Mar 2, 2021 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Development Officer
1,465——0Feb 27, 2021Mar 2, 2021 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
5,904——81,633Sep 1, 2020Sep 4, 2020 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
11,336——11,336Sep 1, 2020Sep 4, 2020 ↗View →
Other insiders · NVCR
Loading peer insiders…
About this filer
CIK 0001822879
ROLE
Chief Development Officer
PRIMARY
NVCR
COMPANIES
1
ACTIVE SINCE
Sep 2020
MARKETPEEL · /INSIDER/0001822879DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback